# BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma

> **NCT03502577** · PHASE1 · TERMINATED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 19 (actual)

## Conditions studied

- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma

## Interventions

- **BIOLOGICAL:** BCMA-specific CAR-expressing T Lymphocytes
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Gamma-Secretase Inhibitor LY3039478
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacokinetic Study

## Key facts

- **NCT ID:** NCT03502577
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-23
- **Primary completion:** 2022-04-20
- **Final completion:** 2022-04-20
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Closed per SRC Low Accrual Policy
- **Last updated:** 2024-01-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03502577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03502577, "BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03502577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*